ASCENDIS PHARMA ON THE CLIFF EDGE
KEEP ALERTS SET FOR A BREAK OF $105, WHICH COULD RESULT IN A VERY NASTY FALL BACK DOWN TO THE GAP UP LEVEL $75,
AVERAGE ANALYSTS ESTIMATE $162.20
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
AVERAGE ANALYSTS ESTIMATE $162.20
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
1) Download our Mobile App >> link-to.app/dexwirenews
2) Join our Telegram >> t.me/DEXWireNews
3) Sign Up for Text Alerts >>
dexwirenews.com/TEXT
4) Follow @DEXWireNews on Social Media
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.